Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Long-Term Debt Repayments: 2013-2020

Historic Long-Term Debt Repayments for Viridian Therapeutics, Inc.\DE (VRDN) over the last 7 years, with Dec 2020 value amounting to $10.3 million.

  • Viridian Therapeutics, Inc.\DE's Long-Term Debt Repayments rose 796.00% to $9.0 million in Q4 2020 from the same period last year, while for Dec 2020 it was $11.3 million, marking a year-over-year increase of 105.33%. This contributed to the annual value of $10.3 million for FY2020, which is 341.19% up from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Long-Term Debt Repayments stood at $10.3 million for FY2020, which was up 341.19% from $2.3 million recorded in FY2019.
  • Viridian Therapeutics, Inc.\DE's Long-Term Debt Repayments' 5-year high stood at $10.3 million during FY2020, with a 5-year trough of $333,000 in FY2016.
  • Moreover, its 2-year median value for Long-Term Debt Repayments was $6.3 million (2019), whereas its average is $6.3 million.
  • Data for Viridian Therapeutics, Inc.\DE's Long-Term Debt Repayments shows a peak YoY soared of 1,301.50% (in 2017) over the last 5 years.
  • Over the past 4 years, Viridian Therapeutics, Inc.\DE's Long-Term Debt Repayments (Yearly) stood at $333,000 in 2016, then spiked by 1,301.50% to $4.7 million in 2017, then reached $2.3 million in 2019, then soared by 341.19% to $10.3 million in 2020.